携手共进：益生菌联合美沙拉嗪治疗溃疡性结肠炎的进展

Working Together: Advances in Probiotics Combined with Mesalazine in the Treatment of Ulcerative Colitis

摘要: 溃疡性结肠炎是一种以肠道为主要发病部位的慢性炎症性病变，常用的传统药物有糖皮质激素、氨基水杨酸制剂、免疫制剂等，其中氨基水杨酸制剂为治疗该病的主要药物，美沙拉嗪为此类药物的代表，但该病治愈难度大且极易发作，大多药物只能暂时缓解患者的不适，因此该疾病严重影响着患者的工作和生活。近年来，微生态制剂应用于溃疡性结肠炎的治疗受到了广泛的关注，通过临床试验证明了益生菌联合美沙拉嗪治疗溃疡性结肠炎是一种值得推广的治疗方法，为溃疡性结肠炎的治疗打开了一道新的大门。本文针对益生菌联合美沙拉嗪的治疗现状进行归纳总结。

Abstract: Ulcerative colitis is a high-risk factor for intestinal lesions, involving chronic inflammation. Tradi-tional Chinese medicine, along with glucocorticoid preparations, immune modulators, and amino acid-based treatments, is commonly used as the primary approach for managing the disease. Salazosulfapyridine represents one such medication; however, curing the disease proves challeng-ing, and recurrence is common. Most drugs can only provide temporary relief from the patient’s discomfort, so the disease seriously affects the patients’ work and life. In recent years, the applica-tion of probiotics in the treatment of ulcerative colitis has received extensive attention. Clinical tri-als have proved that probiotics combined with mesalazine in the treatment of ulcerative colitis is a treatment method worthy of promotion, which opens a new door for the treatment of ulcerative co-litis. This article summarizes the current status of probiotics combined with mesalazine.